The connection in the late 2016 beetwen Acute Myelogenous Leukemia (AML) and dihydroorotate dehydrogenase (hDHODH), a key enzyme in pyrimidine biosynthesis, has attracted significant interest from pharmaceutical companies who have recognized a possible new therapeutic target for AML. In 2018, using a bioisosteric approach supported by structure-based techniques, we discovered MEDS433, a potent hDHODH inhibitor (IC50 = 1.2 nM), able to induce myeloid differentiation in AML cell lines (THP1 and U937) in the low nM range (EC50 = 40 and 26 nM), which shows better qualities than brequinar (EC50 = 249 nM on THP1 and 189 nM on U937), currently in phase I/II clinical trial for AML. These incredible in vitro results encouraged us to deeper the MEDS433 properties in order to optimize the design of the future certified preclinical study necessary to open the doors of the Phase I clinical trial. In this occasion, the pharmacokinetics, metabolism, toxicity as well as the in vivo efficacy in leukemic xenograft mouse model (IP, PO) of MEDS433 are presented. The strategy that allowed the discovery of MEDS700, a MEDS433 backup compound, superior to MEDS433 itself in terms of in vitro efficacy and minor toxicity is also presented.

Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic

Marta Giorgis
First
;
Stefano Sainas;Paola Circosta;Marilena Marraudino;Brigitta Bonaldo;Stefano Gotti;Marta Alberti;Agnese Chiara Pippione;Chiara Vigato;Donatella Boschi;Giuseppe Saglio;Marco Lucio Lolli
2022-01-01

Abstract

The connection in the late 2016 beetwen Acute Myelogenous Leukemia (AML) and dihydroorotate dehydrogenase (hDHODH), a key enzyme in pyrimidine biosynthesis, has attracted significant interest from pharmaceutical companies who have recognized a possible new therapeutic target for AML. In 2018, using a bioisosteric approach supported by structure-based techniques, we discovered MEDS433, a potent hDHODH inhibitor (IC50 = 1.2 nM), able to induce myeloid differentiation in AML cell lines (THP1 and U937) in the low nM range (EC50 = 40 and 26 nM), which shows better qualities than brequinar (EC50 = 249 nM on THP1 and 189 nM on U937), currently in phase I/II clinical trial for AML. These incredible in vitro results encouraged us to deeper the MEDS433 properties in order to optimize the design of the future certified preclinical study necessary to open the doors of the Phase I clinical trial. In this occasion, the pharmacokinetics, metabolism, toxicity as well as the in vivo efficacy in leukemic xenograft mouse model (IP, PO) of MEDS433 are presented. The strategy that allowed the discovery of MEDS700, a MEDS433 backup compound, superior to MEDS433 itself in terms of in vitro efficacy and minor toxicity is also presented.
2022
3rd MMCS: Shaping Medicinal Chemistry for the New Decade
Rome, Italy
27- 29 July 2022
3rd MMCS: Shaping Medicinal Chemistry for the New Decade
130
130
Marta Giorgis, Stefano Sainas, Paola Circosta, Alice Passoni, Renzo Bagnati, Marilena Marraudino, Brigitta Bonaldo, Stefano Gotti, Riccardo Miggiano, ...espandi
File in questo prodotto:
File Dimensione Formato  
MMCS2022_BOOKofABSTRACT.pdf

Accesso riservato

Descrizione: Book of Abstract
Tipo di file: MATERIALE NON BIBLIOGRAFICO
Dimensione 3.21 MB
Formato Adobe PDF
3.21 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1886271
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact